DelveInsight’s, “Crohn’s Disease Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Crohn’s Disease Pipeline Report

• DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
• The leading companies working in the Crohn’s Disease Market include Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
• Promising Crohn’s Disease Pipeline Therapies in the various stages of development include Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
• January 2024: Pfizer announced a study of Phase 3 clinical trials for Etrasimod. This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn’s disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics).
• January 2024: AstraZeneca announced a study of Phase 1 clinical trials for AZD7798. This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn’s disease.
• January 2024: AbbVie announced a study of Phase 3 clinical trials for Risankizumab SC. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn’s Disease.
• January 2024: Prometheus Biosciences Inc., announced a study of Phase 2 clinical trials for PRA023 IV. The purpose of this study is to assess the safety and efficacy of PRA023 in participants with moderately to severely active Crohn’s Disease.

 

Request a sample and discover the recent advances in Crohn’s Disease Treatment Drugs @ Crohn’s Disease Pipeline Report

 

In the Crohn’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Crohn’s Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Crohn’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively.

 

Find out more about Crohn’s Disease Therapeutics Assessment @ Crohn’s Disease Preclinical and Discovery Stage Products

 

Crohn’s Disease Emerging Drugs Profile

• Guselkumab: Janssen
• RHB-104: RedHill Biopharma

 

Crohn’s Disease Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the Crohn’s Disease therapies. The Crohn’s Disease companies which have their Crohn’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Janseen.

 

DelveInsight’s Crohn’s Disease pipeline report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.
• Molecule Type

 

Crohn’s Disease Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Crohn’s Disease Pipeline Therapies @ Crohn’s Disease Clinical Trials Assessment

 

Scope of the Crohn’s Disease Pipeline Report

• Coverage- Global
• Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
• Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

 

Dive deep into rich insights for new drugs for Crohn’s Disease Treatment, Visit @ Crohn’s Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Crohn’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Crohn’s Disease – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Crohn’s Disease Collaboration Deals
9. Late Stage Products (Registered)
10. Infliximab biosimilar: Amgen
11. Drug profiles in the detailed report…..
12. Late Stage Products (Phase III)
13. Guselkumab: Janssen
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II/III)
16. ABX464: Pfizer
17. Drug profiles in the detailed report…..
18. Mid Stage Products (Phase II)
19. Mocravimod: Priothera
20. Drug profiles in the detailed report…..
21. Early Stage Products (Phase I)
22. IMU-856: Immunic
23. Drug profiles in the detailed report…..
24. Preclinical Stage Products
25. INV-88: Innovimmune Biotherapeutics
26. Drug profiles in the detailed report…..
27. Discovery Stage Products
28. DNL975: Denali Therapeutics
29. Inactive Products
30. Crohn’s Disease Key Companies
31. Crohn’s Disease Key Products
32. Crohn’s Disease- Unmet Needs
33. Crohn’s Disease- Market Drivers and Barriers
34. Crohn’s Disease- Future Perspectives and Conclusion
35. Crohn’s Disease Analyst Views
36. Crohn’s Disease Key Companies
37. Appendix

 

For further information on the Crohn’s Disease Pipeline therapeutics, reach out to Crohn’s Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting